PT  - JOURNAL ARTICLE
AU  - Lonergan, Peter E.
AU  - Washington, Samuel L.
AU  - Branagan, Linda
AU  - Gleason, Nathaniel
AU  - Pruthi, Raj S.
AU  - Carroll, Peter R.
AU  - Odisho, Anobel Y.
TI  - Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19
AID  - 10.1101/2020.04.10.20061259
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.10.20061259
4099  - http://medrxiv.org/content/early/2020/04/15/2020.04.10.20061259.short
4100  - http://medrxiv.org/content/early/2020/04/15/2020.04.10.20061259.full
AB  - Background The emergence of the coronavirus disease 2019 (COVID-19) pandemic in March 2020 created unprecedented challenges in the provision of scheduled ambulatory cancer care. As a result, there has been a renewed focus on video consultations as a means to continue ambulatory care.Objective To characterize the increase in video visits at the University of California, San Francisco Comprehensive Cancer Center in response to COVID-19 and compare demographics/appointment data from January 1, 2020 and in the 3 weeks after transition to video visits.Methods Demographics and appointment data (dates, visit types, and departments) were abstracted from the Electronic Health Record reporting database. Video visits were performed using a HIPAA-compliant video conferencing platform with a pre-existing workflow.Results In 17 departments and divisions at the Cancer Center, 2,284 video visits were performed in the pre-COVID-19 period (average 208 ± 75 per week) and 3,015 performed in the 3-week post-COVID-19 period (average 1,005 ± 149 per week). The proportion of video visits increased from 7-18% to 54-68%, between the pre- and post-COVID-19 periods without any disparity based on race/ethnicity, primary language, or insuranceConclusions In a remarkably brief period of time, we rapidly scaled the utilization of telehealth in response to COVID-19 and maintained access to complex oncologic care at a time of social distancing.Competing Interest StatementDr. Odisho was a consultant for VSee from December 2019 to January 2020.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOn request